A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40–120 mg/day) in patients with major depressive disorder

OBJECTIVE: Levomilnacipran ER is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI) approved for the treatment of major depressive disorder (MDD). Efficacy and safety have been evaluated in five Phase II/III studies, four of which met the pre-specified primary efficacy out...

Descripción completa

Detalles Bibliográficos
Autores principales: Gommoll, Carl P., Greenberg, William M., Chen, Changzheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937636/
https://www.ncbi.nlm.nih.gov/pubmed/27536449
http://dx.doi.org/10.3109/21556660.2014.884505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937636/
https://www.ncbi.nlm.nih.gov/pubmed/27536449
http://dx.doi.org/10.3109/21556660.2014.884505

Ejemplares similares